Early Phase I Study of A Window of Opportunity Strategy for Targeted Pathway Inhibition in Patients With Pancreatic Ductal Adenocarcinoma
The purpose of this early phase I study is to determine how cobimetinib or olaparib works in patients with pancreatic cancer that can be removed by surgery. Validation of cobimetinib and olaparib molecular targets will be explored by comparing pre-treatment biopsies with post-treatment resection specimens. This knowledge will help design future biomarker driven trials to determine whether giving cobimetinib plus olaparib will work better than standard treatments in patients with pancreatic cancer.
Study ID: STUDY00019211
Trial Phase: Phase I
Trial Sponsor: Oregon Health & Science University Knight Cancer Institute
Therapies Used in This Trial: Olaparib, Cobimetinib